tiprankstipranks
Advertisement
Advertisement

PHAR Stock Latest News

Pharming Group Wins Positive EMA Panel Backing for Joenja in Rare APDS
Company AnnouncementsPharming Group Wins Positive EMA Panel Backing for Joenja in Rare APDS
2d ago
6K
PHAR
Pharming announces approval of Joenja in Japan for patients aged 4 years and old
PremiumThe Fly
Pharming announces approval of Joenja in Japan for patients aged 4 years and old
5d ago
PHAR
Pharming Group Wins Landmark Japan Approval for Joenja in Pediatric and Adult APDS
PremiumCompany Announcements
Pharming Group Wins Landmark Japan Approval for Joenja in Pediatric and Adult APDS
5d ago
6K
PHAR
Pharming price target lowered to $41 from $42 at Oppenheimer
PremiumThe Fly
Pharming price target lowered to $41 from $42 at Oppenheimer
16d ago
PHAR
Pharming: Solid Execution, Resilient Revenue, and Joenja Growth Support Buy Rating Ahead of Key Leniolisib Catalysts
PremiumRatings
Pharming: Solid Execution, Resilient Revenue, and Joenja Growth Support Buy Rating Ahead of Key Leniolisib Catalysts
17d ago
PHAR
Pharming Group Posts Strong 2025 Growth, Turns Profitable and Lifts 2026 Outlook
PremiumCompany AnnouncementsPharming Group Posts Strong 2025 Growth, Turns Profitable and Lifts 2026 Outlook
17d ago
6K
PHAR
PHAR Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
PHAR Upcoming Earnings Report: What to Expect?
19d ago
PHAR
Pharming Group Sets 2026 Guidance and Showcases Rare Disease Pipeline at Investor Day
Premium
Company Announcements
Pharming Group Sets 2026 Guidance and Showcases Rare Disease Pipeline at Investor Day
2M ago
6K
PHAR
Morning Movers: Disney dips following fourth quarter earnings
PremiumThe Fly
Morning Movers: Disney dips following fourth quarter earnings
2M ago
DIS
DVN
Pharming to host virtual investor day
PremiumThe Fly
Pharming to host virtual investor day
2M ago
PHAR
Pharming receives CRL from U.S. FDA for sNDA for Joenja
PremiumThe Fly
Pharming receives CRL from U.S. FDA for sNDA for Joenja
2M ago
PHAR
FDA Calendar: These Are the Remaining Drug Approvals Anticipated This Month
PremiumMarket News
FDA Calendar: These Are the Remaining Drug Approvals Anticipated This Month
2M ago
AQST
IRON
Pharming Group Beats 2025 Revenue Guidance and Sets February Investor Day
PremiumCompany AnnouncementsPharming Group Beats 2025 Revenue Guidance and Sets February Investor Day
3M ago
6K
PHAR
Pharming price target raised to $42 from $41 at Oppenheimer
Premium
The Fly
Pharming price target raised to $42 from $41 at Oppenheimer
5M ago
PHAR
Pharming Group Reports Strong Q3 2025 Growth
Premium
Company Announcements
Pharming Group Reports Strong Q3 2025 Growth
5M ago
PHAR
Pharming Group Reports Strong Q3 2025 Financial Growth and Strategic Updates
PremiumCompany Announcements
Pharming Group Reports Strong Q3 2025 Financial Growth and Strategic Updates
5M ago
6K
PHAR
Pharming Group to Present New Data at ACAAI 2025
PremiumCompany Announcements
Pharming Group to Present New Data at ACAAI 2025
5M ago
6K
PHAR
Pharming Group Announces Restructuring to Cut Costs and Boost Growth
PremiumCompany Announcements
Pharming Group Announces Restructuring to Cut Costs and Boost Growth
6M ago
6K
PHAR
Pharming announces 20% net reduction in non-commercial, non-medical headcount
PremiumThe Fly
Pharming announces 20% net reduction in non-commercial, non-medical headcount
6M ago
PHAR
Pharming Group’s Leniolisib Gains FDA Approval for Pediatric Use, Expanding Market Potential
PremiumRatingsPharming Group’s Leniolisib Gains FDA Approval for Pediatric Use, Expanding Market Potential
6M ago
PHAR
Pharming Group’s Leniolisib Receives FDA Priority Review for Pediatric APDS Treatment
Premium
Company Announcements
Pharming Group’s Leniolisib Receives FDA Priority Review for Pediatric APDS Treatment
6M ago
6K
PHAR
Pharming Group Joins Euronext AMX® Index Reflecting Growth Momentum
Premium
Company Announcements
Pharming Group Joins Euronext AMX® Index Reflecting Growth Momentum
7M ago
6K
PHAR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >